Asset Details
Do you wish to reserve the book?
Sustained Belinostat‐Induced Metabolic Response and Tolerability in Heavily Pretreated Relapsed/Refractory Angioimmunoblastic T‐Cell Lymphoma: A Case Report
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sustained Belinostat‐Induced Metabolic Response and Tolerability in Heavily Pretreated Relapsed/Refractory Angioimmunoblastic T‐Cell Lymphoma: A Case Report
Do you wish to request the book?
Sustained Belinostat‐Induced Metabolic Response and Tolerability in Heavily Pretreated Relapsed/Refractory Angioimmunoblastic T‐Cell Lymphoma: A Case Report
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Sustained Belinostat‐Induced Metabolic Response and Tolerability in Heavily Pretreated Relapsed/Refractory Angioimmunoblastic T‐Cell Lymphoma: A Case Report
2026
Overview
Angioimmunoblastic T‐cell lymphoma (AITL), a rare and aggressive subtype of peripheral T‐cell lymphoma (PTCL), often demonstrates resistance to standard therapies. The optimal therapeutic approach for relapsed/refractory (R/R) AITL remains therefore uncertain and challenging, with an unmet need for effective treatment options. Given the role of epigenetic alterations in AITL lymphomagenesis, the development of drugs targeting epigenetics may present a promising therapeutic approach. Belinostat, a histone deacetylase (HDAC) inhibitor, induced durable partial remission in heavily pretreated relapsed/refractory angioimmunoblastic T‐cell lymphoma, highlighting its potential as an effective therapeutic option when standard treatments and stem cell transplantation are unsuitable. Key Clinical Message In patients with heavily pretreated relapsed/refractory AITL, HDAC inhibition can achieve long‐lasting metabolic control with minimal toxicity, even after multiple relapses. When stem cell transplantation is declined or unsuitable, belinostat as an epigenetic therapy offers a rational, patient‐centered alternative to maintain disease control and preserve quality of life.
